P0168 Role of Multidisciplinary Teams in Breast Cancer Adjuvant Therapy: an Analysis of Decision-Making Related Factors
Yue Liang,Xiaosong Chen,Jiayi Wu,Ou Huang,Yu Zong,Yan Mao,Yafen Li,Weiguo Chen,Li Zhu,Jianrong He,Qiong Fang,Nan Zhang,Kunwei Shen
DOI: https://doi.org/10.1016/j.ejca.2015.06.095
IF: 10.002
2015-01-01
European Journal of Cancer
Abstract:Background When deciding the adjuvant treatment strategy for breast cancer patients, the attending doctor’s opinion may be affected by the result from multidisciplinary team (MDT) consultation. We aimed is to find out which clinicopathological factors would be more likely to affect initial treatment strategy from the attending doctor and the significance of MDT consultation in it. Methods In 2013, 410 patients with invasive breast cancer received MDT consultation at the Comprehensive Breast Health Center, Shanghai Ruijin Hospital. Chi-square analysis and multivariate logistic regression analysis were used to define the factors associated with the disagreement between the attending doctor and MDT panel. Findings Disagreement between the attending doctor and MDT panel were seen in 81 cases (19.8%), which related to all three categories in adjuvant treatment: chemotherapy (4.1%), radiation therapy (5.4%), and endocrine therapy (5.2%). For chemotherapy, molecular subtypes (X2 = 10.669, p = 0.014) were significantly correlated with the disagreement, as was lymph node staging (X2 = 6.168, p = 0.046) for radiation therapy. For endocrine therapy, menstrual status (X2 = 3.927, p = 0.048) and family history (X2 = 4.725, p = 0.03) were significantly correlated with disagreement. In multivariate logistic regression analysis, changing of endocrine therapy regimens was more likely to be seen in postmenopausal patients than in premenopausal patients (odds ratio (OR) 3.298; 95% confidence interval (CI) 1.065–10.207; p = 0.038). Family history was also a predictive factor of decision changing (OR 0.183; 95% CI 0.051–0.653; p = 0.009). Interpretation Molecular subtypes, lymph node staging, and menstrual status were crucial factors in the breast cancer MDT decision-making process and most controversial cases presented with these factors. More attention should be paid to these factors to offer standardised and individualised adjuvant therapy for patients with breast cancer. When deciding the adjuvant treatment strategy for breast cancer patients, the attending doctor’s opinion may be affected by the result from multidisciplinary team (MDT) consultation. We aimed is to find out which clinicopathological factors would be more likely to affect initial treatment strategy from the attending doctor and the significance of MDT consultation in it. In 2013, 410 patients with invasive breast cancer received MDT consultation at the Comprehensive Breast Health Center, Shanghai Ruijin Hospital. Chi-square analysis and multivariate logistic regression analysis were used to define the factors associated with the disagreement between the attending doctor and MDT panel. Disagreement between the attending doctor and MDT panel were seen in 81 cases (19.8%), which related to all three categories in adjuvant treatment: chemotherapy (4.1%), radiation therapy (5.4%), and endocrine therapy (5.2%). For chemotherapy, molecular subtypes (X2 = 10.669, p = 0.014) were significantly correlated with the disagreement, as was lymph node staging (X2 = 6.168, p = 0.046) for radiation therapy. For endocrine therapy, menstrual status (X2 = 3.927, p = 0.048) and family history (X2 = 4.725, p = 0.03) were significantly correlated with disagreement. In multivariate logistic regression analysis, changing of endocrine therapy regimens was more likely to be seen in postmenopausal patients than in premenopausal patients (odds ratio (OR) 3.298; 95% confidence interval (CI) 1.065–10.207; p = 0.038). Family history was also a predictive factor of decision changing (OR 0.183; 95% CI 0.051–0.653; p = 0.009). Molecular subtypes, lymph node staging, and menstrual status were crucial factors in the breast cancer MDT decision-making process and most controversial cases presented with these factors. More attention should be paid to these factors to offer standardised and individualised adjuvant therapy for patients with breast cancer.